

Docket No. 245437US0



DFW  
\$

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Fumiyuki SHIRAI, et al.

SERIAL NO: 10/706,999

GAU: 1625

FILED: November 14, 2003

EXAMINER: P.L. MORRIS

FOR: PYRAZOLE DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☒ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

02/27/2006 SZENDIE1 00000102 10706999

01 FC:1806

180.00 OP

Customer Number


**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.  
Norman F. Oblon

James J. Kelly, Ph.D.  
Registration No. 41,504

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 245437US0		SERIAL NO. 10/706,999	
<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center; margin-right: 10px;">  </div> <div> <p>LIST OF REFERENCES CITED BY APPLICANT</p> </div> </div>				APPLICANT Fumiyuki SHIRAI, et al.			
				FILING DATE November 14, 2003		GROUP 1625	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	AA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2005/277678	12/15/05	LOHRAY ET AL			
	AB	2003/162824	08/28/03	KRUL			
	AC	6,506,747	01/14/03	BETAGERI ET AL			
	AD	5,550,147	08/27/96	MATSUO ET AL			
	AE	5,670,533	09/23/97	MATSUO ET AL			
	AF	5,134,142	07/28/92	MATSUO ET AL			
	AG	5,051,518	09/24/91	MURRAY ET AL			
	AH	5,298,521	03/29/94	FERRO			
	AI	4,826,868	05/02/89	WACHTER ET AL			
	AJ	5,164,381	11/17/92	WACHTER ET AL			
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
					YES	NO	
	AO	EP 1 104 759	06/06/01	EUROPE	X		
	AP	WO 2004/050632	06/17/04	WIPO	X		
	AQ	WO 00/18741	04/06/00	WIPO	X		
	AR	WO 01/81332	11/01/01	WIPO	X		
	AS	WO 00/66562	11/09/00	WIPO	X		
	AT	WO 96/14302	05/17/96	WIPO	X		
	AU	CN 11631339	08/11/04	CHINA (w/English Abstract)			
	AV						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AW	Communication Pursuant to Article 96(2) from European Patent Office dated September 6, 2005.					
	AX	D.E. Griswold, et al., "Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date", Medicinal Research Reviews, vol. 16, No. 2, 1996, pp. 181-206.					
	AY	K.N. Zelenin, et al., "", Chemistry of Heterocyclic Compounds, vol. 38, No. 6, 2002, pp. 668-676.					
	AZ	G.W. Kauffman, et al., "QSAR and k-Nearest Neighbor Classification Analysis of Selective Cyclooxygenase-2 Inhibitors Using Topologically-Based Numerical Descriptors", J. Chem. Inf. Comput. Sci., vol. 41, 2001, pp. 1553-1560.				<input checked="" type="checkbox"/> Additional References sheet(s) attached	
Examiner							
Date Considered							
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO.  245437US0		SERIAL NO.  10/706,999			
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT  Fumiyuki SHIRAI, et al.					
				FILING DATE  November 14, 2003				GROUP  1625	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)									
	AAA	P. Chavatte, et al., "Three-Dimensional Quantitative Structure-Activity Relationships of Cyclo-oxygenase-2 (COX-2) Inhibitors: A Comparative Molecular Field Analysis", J. Med. Chem., vol. 44, 2001, pp. 3223-3230.							
	AAB	X. Wang, et al., "Practical Synthesis of 1,3-diaryl-5-alkylpyrazoles By A Highly Regioselective N-arylation of 3,5-disubstituted Pyrazoles with 4-fluoronitrobenzene", Tetrahedron Letters, vol. 41, 2000, pp. 5321-5324.							
	AAC	K. Tsuji, et al., "Studies on Anti-Inflammatory Agents. V. <sup>1st</sup> " Synthesis and Pharmacological Properties of 3-(Difluoromethyl)-1-(4-methoxyphenyl)-5-[4-(methylsulfinyl)phenyl]pyrazole and Related Compounds, Chem. Pharm. Bull., vol. 45, No. 9, 1997, pp. 1475-1481.							
	AAD	K. Tsuji, et al., "Studies on Anti-Inflammatory Agents. V. <sup>1st</sup> " Synthesis and Pharmacological Properties of 1,5-Diarylpyrazoles and Related Derivatives", Chem. Pharm. Bull., vol. 45, No. 6, 1997, pp. 987-995.							
	AAE	T.D. Penning, et al., "Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)", J. Med. Chem., vol. 40, 1997, pp. 1347-1365.							
	AAF	W. Murray, et al., "Synthesis of 3-(1,5-Diphenyl-3-pyrazolyl)aryl Propanoates", J. Heterocyclic Chem., vol. 27, 1990, pp. 1933-1940.							
	AAG	W. Murray, et al., "A Simple Regioselective Synthesis of Ethyl 1,5-Diarylpyrazole-3-Carboxylates", J. Heterocyclic Chem., vol. 26, 1989, pp. 1389-1392.							
	AAH	M. Mihalic, et al., "Syntheses of the New Indole Derivatives Related to Indomethacin", Groatica Chemica ACTA, vol. 51, No. 1, 1978, pp. 81-92.							
	AAI	K. Zelenin, et al., "5-Hydroxy-4,5-Dihydropyrazoles", Tetrahedron, vol. 51, No. 41, 1995, pp. 11251-11256							
	AAJ	G. Menozzi, et al., "4-Substituted 1,5-Diarylpyrazole, Analogues of Celecoxib: Synthesis and Preliminary Evaluation of Biological Properties", Farmaco, vol. 58, 2003, pp. 795-808.							
	AAK	A. Alberola, et al., "Scope and Limitations in the Regioselective Synthesis of 1,3,5-Trisubstituted Pyrazoles from $\beta$ -Amino Enones and Hydrazine Derivatives. <sup>13</sup> C-Chemical Shift Prediction Rules for 1,3,5-Trisubstituted Pyrazoles", Heterocycles, vol. 55, No. 2, 2001, pp. 331-351.							
	AAL	B. Stanovnik, et al., "Product Class 1: Pyrazoles", Science of Synthesis, vol. 12, 2002, pp. 15-225.							
	AAM								
	AAN								
	AAO								
	AAP								
	AAQ								
Examiner						Date Considered			
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									